605507.SH
Guobang Pharma Ltd.
SSE · Healthcare · Drug Manufacturers - Specialty & Generic · CN
CNY 14.85
+0.34%Oct 23, 2026, 07:59 UTC
Guobang Pharmaceutical reported third-quarter 2026 revenue of RMB 1.446 billion, up 0.19% year over year, and net profit of RMB 130 million, down 39.44%; nine-month revenue was RMB 4.589 billion, up 2.66%, and net profit was RMB 471 million, down 29.67%.
Source:Sep 22, 2026, 09:38 UTC
Guobang Pharmaceutical Group and Alibaba Cloud announced a strategic partnership at the 2026 Yunqi Conference in Hangzhou, covering organizational transformation, marketing and supply chain, and AI-enabled R&D.
Source:Sep 15, 2026, 09:12 UTC
Guobang Pharma's wholly owned subsidiary Zhejiang Guobang Pharmaceutical received an 'A' status from China's CDE for its injectable-grade glyceryl dipalmitate excipient, clearing it for commercial supply to downstream formulation customers.
Source: